{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,22]],"date-time":"2026-09-22T16:41:02Z","timestamp":1790095262695,"version":"4.0.1"},"reference-count":99,"publisher":"Elsevier BV","issue":"2","license":[{"start":{"date-parts":[[2015,2,1]],"date-time":"2015-02-01T00:00:00Z","timestamp":1422748800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"}],"content-domain":{"domain":["cancertreatmentreviews.com","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Cancer Treatment Reviews"],"published-print":{"date-parts":[[2015,2]]},"DOI":"10.1016\/j.ctrv.2014.12.001","type":"journal-article","created":{"date-parts":[[2014,12,8]],"date-time":"2014-12-08T17:55:35Z","timestamp":1418061335000},"page":"61-68","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":50,"title":["Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment"],"prefix":"10.1016","volume":"41","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9064-0113","authenticated-orcid":false,"given":"Carmen","family":"Criscitiello","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giulia","family":"Viale","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lucia","family":"Gelao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Angela","family":"Esposito","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"De Laurentiis","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sabino","family":"De Placido","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Michele","family":"Santangelo","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Aron","family":"Goldhirsch","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Giuseppe","family":"Curigliano","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1016\/j.ctrv.2014.12.001_b0005","doi-asserted-by":"crossref","first-page":"305","DOI":"10.1007\/s00262-011-0974-x","article-title":"Interaction between the skeletal and immune systems in cancer: mechanisms and clinical implications","volume":"60","author":"Terpos","year":"2011","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2014.12.001_b0010","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1007\/s11914-007-0024-y","article-title":"The RANKL\/RANK\/OPG pathway","volume":"5","author":"Boyce","year":"2007","journal-title":"Curr Osteoporosis Rep"},{"key":"10.1016\/j.ctrv.2014.12.001_b0015","doi-asserted-by":"crossref","first-page":"292","DOI":"10.1038\/nri2062","article-title":"Osteoimmunology: shared mechanisms and crosstalk between the immune and bone systems","volume":"7","author":"Takayanagi","year":"2007","journal-title":"Nat Rev Immunol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0020","doi-asserted-by":"crossref","first-page":"250","DOI":"10.1016\/j.autrev.2008.07.038","article-title":"Osteoimmunology \u2013 the hidden immune regulation of bone","volume":"8","author":"Caetano-Lopes","year":"2009","journal-title":"Autoimmun Rev"},{"key":"10.1016\/j.ctrv.2014.12.001_b0025","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1146\/annurev.immunol.20.100301.064753","article-title":"RANK-L and RANK: T cells, bone loss, and mammalian evolution","volume":"20","author":"Theill","year":"2002","journal-title":"Annu Rev Immunol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0030","doi-asserted-by":"crossref","first-page":"5050","DOI":"10.1210\/endo.142.12.8536","article-title":"Minireview: the OPG\/RANKL\/RANK system","volume":"142","author":"Khosla","year":"2001","journal-title":"Endocrinology"},{"key":"10.1016\/j.ctrv.2014.12.001_b0035","first-page":"345","article-title":"Receptor activator of nuclear factor-kappaB ligand and osteoprotegerin: maintaining the balance to prevent bone loss","volume":"5","author":"Trouvin","year":"2010","journal-title":"Clin Interv Aging"},{"key":"10.1016\/j.ctrv.2014.12.001_b0040","doi-asserted-by":"crossref","first-page":"2412","DOI":"10.1101\/gad.13.18.2412","article-title":"RANK is essential for osteoclast and lymph node development","volume":"13","author":"Dougall","year":"1999","journal-title":"Genes Dev"},{"key":"10.1016\/j.ctrv.2014.12.001_b0045","doi-asserted-by":"crossref","first-page":"749","DOI":"10.1172\/JCI11089","article-title":"Interactions between immune and bone cells: new insights with many remaining questions","volume":"106","author":"Lorenzo","year":"2000","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ctrv.2014.12.001_b0050","doi-asserted-by":"crossref","first-page":"25190","DOI":"10.1074\/jbc.272.40.25190","article-title":"TRANCE is a novel ligand of the tumor necrosis factor receptor family that activates c-Jun N-terminal kinase in T cells","volume":"272","author":"Wong","year":"1997","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2014.12.001_b0055","doi-asserted-by":"crossref","first-page":"251","DOI":"10.1016\/S1359-6101(03)00027-3","article-title":"Biology of the TRANCE axis","volume":"14","author":"Walsh","year":"2003","journal-title":"Cytokine Growth Factor Rev"},{"key":"10.1016\/j.ctrv.2014.12.001_b0060","doi-asserted-by":"crossref","first-page":"852","DOI":"10.1182\/blood-2004-09-3662","article-title":"A crucial role for reactive oxygen species in RANKL-induced osteoclast differentiation","volume":"106","author":"Lee","year":"2005","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.12.001_b0065","doi-asserted-by":"crossref","first-page":"221","DOI":"10.1586\/14737140.7.2.221","article-title":"Key roles of the OPG\u2013RANK\u2013RANKL system in bone oncology","volume":"7","author":"Baud\u2019huin","year":"2007","journal-title":"Expert Rev Anticancer Ther"},{"key":"10.1016\/j.ctrv.2014.12.001_b0070","doi-asserted-by":"crossref","first-page":"329","DOI":"10.3389\/fonc.2013.00329","article-title":"Effects of RANKL-targeted therapy in immunity and cancer","volume":"3","author":"Cheng","year":"2014","journal-title":"Front Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0075","doi-asserted-by":"crossref","first-page":"423","DOI":"10.1016\/j.immuni.2008.06.015","article-title":"The tumor necrosis factor family receptors RANK and CD40 cooperatively establish the thymic medullary microenvironment and self-tolerance","volume":"29","author":"Akiyama","year":"2008","journal-title":"Immunity"},{"key":"10.1016\/j.ctrv.2014.12.001_b0080","doi-asserted-by":"crossref","first-page":"4425","DOI":"10.4049\/jimmunol.173.7.4425","article-title":"Bcl-xL is critical for dendritic cell survival in vivo","volume":"173","author":"Hon","year":"2004","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0085","doi-asserted-by":"crossref","first-page":"3646","DOI":"10.1182\/blood-2002-01-0312","article-title":"Long-lived immature dendritic cells mediated by TRANCE\u2013RANK interaction","volume":"100","author":"Cremer","year":"2002","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.12.001_b0090","doi-asserted-by":"crossref","first-page":"30202","DOI":"10.1074\/jbc.M403968200","article-title":"A novel in vivo role for osteoprotegerin ligand in activation of monocyte effector function and inflammatory response","volume":"279","author":"Seshasayee","year":"2004","journal-title":"J Biol Chem"},{"key":"10.1016\/j.ctrv.2014.12.001_b0095","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.4049\/jimmunol.166.3.1482","article-title":"Osteoprotegerin, a crucial regulator of bone metabolism, also regulates B cell development and function","volume":"166","author":"Yun","year":"2001","journal-title":"Journal Immunol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0100","doi-asserted-by":"crossref","first-page":"933","DOI":"10.1189\/jlb.0708419","article-title":"Regulation of dendritic cell survival and cytokine production by osteoprotegerin","volume":"86","author":"Chino","year":"2009","journal-title":"J Leukoc Biol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0105","doi-asserted-by":"crossref","first-page":"960","DOI":"10.1038\/ng2076","article-title":"Osteoclast-poor human osteopetrosis due to mutations in the gene encoding RANKL","volume":"39","author":"Sobacchi","year":"2007","journal-title":"Nat Genet"},{"key":"10.1016\/j.ctrv.2014.12.001_b0110","doi-asserted-by":"crossref","first-page":"2673","DOI":"10.1084\/jem.20061775","article-title":"Th17 functions as an osteoclastogenic helper T cell subset that links T cell activation and bone destruction","volume":"203","author":"Sato","year":"2006","journal-title":"J Exp Med"},{"key":"10.1016\/j.ctrv.2014.12.001_b0115","doi-asserted-by":"crossref","first-page":"1345","DOI":"10.1172\/JCI5703","article-title":"IL-17 in synovial fluids from patients with rheumatoid arthritis is a potent stimulator of osteoclastogenesis","volume":"103","author":"Kotake","year":"1999","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ctrv.2014.12.001_b0120","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1093\/jb\/mvt049","article-title":"Immunology and bone","volume":"154","author":"Danks","year":"2013","journal-title":"J Biochem"},{"key":"10.1016\/j.ctrv.2014.12.001_b0125","doi-asserted-by":"crossref","first-page":"763","DOI":"10.1038\/nrd3794","article-title":"Targeting IL-17 and TH17 cells in chronic inflammation","volume":"11","author":"Miossec","year":"2012","journal-title":"Nat Rev Drug Discovery"},{"key":"10.1016\/j.ctrv.2014.12.001_b0130","doi-asserted-by":"crossref","first-page":"149","DOI":"10.1016\/j.cell.2004.07.004","article-title":"Tie2\/angiopoietin-1 signaling regulates hematopoietic stem cell quiescence in the bone marrow niche","volume":"118","author":"Arai","year":"2004","journal-title":"Cell"},{"key":"10.1016\/j.ctrv.2014.12.001_b0135","doi-asserted-by":"crossref","first-page":"457","DOI":"10.1038\/nature10783","article-title":"Endothelial and perivascular cells maintain haematopoietic stem cells","volume":"481","author":"Ding","year":"2012","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2014.12.001_b0140","doi-asserted-by":"crossref","DOI":"10.1002\/jbmr.2294","article-title":"Human osteoclasts are inducible immunosuppressive cells in response to T cell-derived IFN-gamma and CD40 ligand in vitro","author":"Li","year":"2014","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2014.12.001_b0145","doi-asserted-by":"crossref","first-page":"1565","DOI":"10.1126\/science.1203486","article-title":"Cancer immunoediting: integrating immunity\u2019s roles in cancer suppression and promotion","volume":"331","author":"Schreiber","year":"2011","journal-title":"Science"},{"key":"10.1016\/j.ctrv.2014.12.001_b0150","doi-asserted-by":"crossref","first-page":"1224","DOI":"10.1038\/nm.2830","article-title":"Silencing of Irf7 pathways in breast cancer cells promotes bone metastasis through immune escape","volume":"18","author":"Bidwell","year":"2012","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2014.12.001_b0155","doi-asserted-by":"crossref","first-page":"92","DOI":"10.1016\/j.ctrv.2007.09.002","article-title":"RANK ligand as a therapeutic target for bone metastases and multiple myeloma","volume":"34","author":"Roodman","year":"2008","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2014.12.001_b0160","doi-asserted-by":"crossref","first-page":"692","DOI":"10.1038\/nature04524","article-title":"Regulation of cancer cell migration and bone metastasis by RANKL","volume":"440","author":"Jones","year":"2006","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2014.12.001_b0165","first-page":"4432","article-title":"Osteoprotegerin inhibits osteolysis and decreases skeletal tumor burden in syngeneic and nude mouse models of experimental bone metastasis","volume":"61","author":"Morony","year":"2001","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.001_b0170","doi-asserted-by":"crossref","first-page":"3722","DOI":"10.1182\/blood-2004-02-0474","article-title":"T cells support osteoclastogenesis in an in vitro model derived from human multiple myeloma bone disease: the role of the OPG\/TRAIL interaction","volume":"104","author":"Colucci","year":"2004","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.12.001_b0175","doi-asserted-by":"crossref","first-page":"109","DOI":"10.1016\/j.lungcan.2007.10.016","article-title":"Spontaneous osteoclastogenesis is a predictive factor for bone metastases from non-small cell lung cancer","volume":"61","author":"Roato","year":"2008","journal-title":"Lung Cancer"},{"key":"10.1016\/j.ctrv.2014.12.001_b0180","doi-asserted-by":"crossref","first-page":"4799","DOI":"10.1158\/0008-5472.CAN-10-3922","article-title":"CD8+ T cells regulate bone tumor burden independent of osteoclast resorption","volume":"71","author":"Zhang","year":"2011","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.001_b0185","doi-asserted-by":"crossref","first-page":"12","DOI":"10.1186\/1471-2407-10-12","article-title":"Bone invading NSCLC cells produce IL-7: mice model and human histologic data","volume":"10","author":"Roato","year":"2010","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2014.12.001_b0190","doi-asserted-by":"crossref","first-page":"5262","DOI":"10.1158\/1078-0432.CCR-07-1157","article-title":"Transforming growth factor-beta and the immune response: implications for anticancer therapy","volume":"13","author":"Wrzesinski","year":"2007","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.001_b0195","doi-asserted-by":"crossref","first-page":"812","DOI":"10.1172\/JCI66776","article-title":"Macrophages eliminate circulating tumor cells after monoclonal antibody therapy","volume":"124","author":"Gul","year":"2014","journal-title":"J Clin Investig"},{"key":"10.1016\/j.ctrv.2014.12.001_b0200","doi-asserted-by":"crossref","first-page":"121","DOI":"10.3109\/1354750X.2012.745166","article-title":"Assessment and clinical implications of RANK\/RANKL\/OPG pathway as markers of bone tumor progression in patients with NET harboring bone metastases","volume":"18","author":"Milone","year":"2013","journal-title":"Biomarkers"},{"key":"10.1016\/j.ctrv.2014.12.001_b0205","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1111\/j.1464-410X.2012.11759.x","article-title":"Serum receptor activator of nuclear factor kappaB ligand (RANKL) levels predict biochemical recurrence in patients undergoing radical prostatectomy","volume":"113","author":"Todenhofer","year":"2014","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2014.12.001_b0210","doi-asserted-by":"crossref","first-page":"201","DOI":"10.5173\/ceju.2011.04.art2","article-title":"Reciprocal cross-talk between Prostaglandin E2 and bone in prostate cancer: a current review","volume":"64","author":"Di Francesco","year":"2011","journal-title":"Cent Eur J Urol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0215","doi-asserted-by":"crossref","first-page":"411","DOI":"10.1038\/nrc3055","article-title":"Cancer to bone: a fatal attraction","volume":"11","author":"Weilbaecher","year":"2011","journal-title":"Nat Rev Cancer"},{"key":"10.1016\/j.ctrv.2014.12.001_b0220","doi-asserted-by":"crossref","first-page":"21","DOI":"10.4065\/78.1.21","article-title":"Review of 1027 patients with newly diagnosed multiple myeloma","volume":"78","author":"Kyle","year":"2003","journal-title":"Mayo Clin Proc"},{"key":"10.1016\/j.ctrv.2014.12.001_b0225","doi-asserted-by":"crossref","first-page":"367","DOI":"10.1196\/annals.1346.041","article-title":"Bisphosphonates: from bench to bedside","volume":"1068","author":"Russell","year":"2006","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2014.12.001_b0230","doi-asserted-by":"crossref","first-page":"102","DOI":"10.2174\/187152012799014977","article-title":"Potential anticancer properties of bisphosphonates: insights from preclinical studies","volume":"12","author":"Clezardin","year":"2012","journal-title":"Anti-Cancer Agents Med Chem"},{"key":"10.1016\/j.ctrv.2014.12.001_b0235","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1007\/s00262-008-0521-6","article-title":"In vivo effects of zoledronic acid on peripheral gammadelta T lymphocytes in early breast cancer patients","volume":"58","author":"Santini","year":"2009","journal-title":"Cancer Immunol Immunother"},{"key":"10.1016\/j.ctrv.2014.12.001_b0240","doi-asserted-by":"crossref","first-page":"11","DOI":"10.1007\/978-1-4419-1050-9_2","article-title":"Activation of gammadelta T cells by bisphosphonates","volume":"658","author":"Thompson","year":"2010","journal-title":"Adv Exp Med Biol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0245","doi-asserted-by":"crossref","first-page":"59","DOI":"10.1200\/JCO.1993.11.1.59","article-title":"Double-blind controlled trial of oral clodronate in patients with bone metastases from breast cancer","volume":"11","author":"Paterson","year":"1993","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0250","doi-asserted-by":"crossref","first-page":"1035","DOI":"10.1046\/j.1365-2141.2001.02851.x","article-title":"Long-term follow-up of a prospective, double-blind, placebo-controlled randomized trial of clodronate in multiple myeloma","volume":"113","author":"McCloskey","year":"2001","journal-title":"Br J Haematol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0255","doi-asserted-by":"crossref","first-page":"872","DOI":"10.1016\/S1470-2045(09)70201-3","article-title":"Adjuvant therapy with oral sodium clodronate in locally advanced and metastatic prostate cancer: long-term overall survival results from the MRC PR04 and PR05 randomised controlled trials","volume":"10","author":"Dearnaley","year":"2009","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0260","doi-asserted-by":"crossref","first-page":"625060","DOI":"10.1155\/2014\/625060","article-title":"The efficacy of bisphosphonates in preventing aromatase inhibitor induced bone loss for postmenopausal women with early breast cancer: a systematic review and meta-analysis","volume":"2014","author":"Anagha","year":"2014","journal-title":"J Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0265","doi-asserted-by":"crossref","first-page":"6863","DOI":"10.1158\/1078-0432.CCR-13-2275","article-title":"Comparative efficacy of bisphosphonates in metastatic breast and prostate cancer and multiple myeloma: a mixed-treatment meta-analysis","volume":"19","author":"Palmieri","year":"2013","journal-title":"Clin Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.001_b0270","doi-asserted-by":"crossref","first-page":"571","DOI":"10.1593\/neo.10282","article-title":"How do bisphosphonates inhibit bone metastasis in vivo?","volume":"12","author":"Fournier","year":"2010","journal-title":"Neoplasia"},{"key":"10.1016\/j.ctrv.2014.12.001_b0275","doi-asserted-by":"crossref","first-page":"464","DOI":"10.1002\/jbmr.1797","article-title":"Monocytes and gammadelta T cells control the acute-phase response to intravenous zoledronate: insights from a phase IV safety trial","volume":"28","author":"Welton","year":"2013","journal-title":"J Bone Miner Res"},{"key":"10.1016\/j.ctrv.2014.12.001_b0280","doi-asserted-by":"crossref","first-page":"1263","DOI":"10.3892\/ijo.2013.1809","article-title":"Cisplatin in combination with zoledronic acid: a synergistic effect in triple-negative breast cancer cell lines","volume":"42","author":"Ibrahim","year":"2013","journal-title":"Int J Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0285","doi-asserted-by":"crossref","first-page":"E1147","DOI":"10.1111\/j.1464-410X.2012.11392.x","article-title":"Zoledronic acid in combination with serine\/threonine phosphatase inhibitors induces enhanced cytotoxicity and apoptosis in hormone-refractory prostate cancer cell lines by decreasing the activities of PP1 and PP2A","volume":"110","author":"Cirak","year":"2012","journal-title":"BJU Int"},{"key":"10.1016\/j.ctrv.2014.12.001_b0290","doi-asserted-by":"crossref","first-page":"955","DOI":"10.3892\/or.2013.2907","article-title":"In vitro antitumor effect of sodium butyrate and zoledronic acid combined with traditional chemotherapeutic drugs: a paradigm of synergistic molecular targeting in the treatment of Ewing sarcoma","volume":"31","author":"Dos Santos","year":"2014","journal-title":"Oncol Rep"},{"key":"10.1016\/j.ctrv.2014.12.001_b0295","doi-asserted-by":"crossref","first-page":"480","DOI":"10.1186\/1471-2407-13-480","article-title":"Influence of zoledronic acid on disseminated tumor cells in bone marrow and survival: results of a prospective clinical trial","volume":"13","author":"Banys","year":"2013","journal-title":"BMC Cancer"},{"key":"10.1016\/j.ctrv.2014.12.001_b0300","doi-asserted-by":"crossref","first-page":"2271","DOI":"10.1093\/annonc\/mdr612","article-title":"Influence of zoledronic acid on disseminated tumor cells in primary breast cancer patients","volume":"23","author":"Solomayer","year":"2012","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0305","doi-asserted-by":"crossref","first-page":"195","DOI":"10.1385\/MO:22:2:195","article-title":"Randomized, open label, prospective study on the effect of zoledronic acid on the prevention of bone metastases in patients with recurrent solid tumors that did not present with bone metastases at baseline","volume":"22","author":"Mystakidou","year":"2005","journal-title":"Med Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0310","first-page":"5295","article-title":"Zoledronic acid as an antimetastatic agent for different human tumor cell lines","volume":"33","author":"Muinelo-Romay","year":"2013","journal-title":"Anticancer Res"},{"key":"10.1016\/j.ctrv.2014.12.001_b0315","doi-asserted-by":"crossref","first-page":"353","DOI":"10.1634\/theoncologist.2012-0261","article-title":"Adjuvant therapy with zoledronic acid in patients with breast cancer: a systematic review and meta-analysis","volume":"18","author":"Valachis","year":"2013","journal-title":"Oncologist"},{"key":"10.1016\/j.ctrv.2014.12.001_b0320","doi-asserted-by":"crossref","first-page":"476","DOI":"10.1016\/j.ctrv.2013.07.003","article-title":"Role of bisphosphonates in postmenopausal women with breast cancer","volume":"40","author":"Gnant","year":"2014","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2014.12.001_b0325","doi-asserted-by":"crossref","first-page":"135","DOI":"10.1016\/j.clon.2012.10.010","article-title":"Bisphosphonates in the adjuvant treatment of breast cancer","volume":"25","author":"Winter","year":"2013","journal-title":"Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0330","doi-asserted-by":"crossref","unstructured":"Mhaskar R, Redzepovic J, Wheatley K, Clark OA, Miladinovic B, Glasmacher A, et al. Bisphosphonates in multiple myeloma. Cochrane Database Syst Rev. 2010:CD003188.","DOI":"10.1002\/14651858.CD003188.pub2"},{"key":"10.1016\/j.ctrv.2014.12.001_b0335","doi-asserted-by":"crossref","first-page":"222","DOI":"10.1007\/s12094-011-0646-5","article-title":"RANKL inhibition: a promising novel strategy for breast cancer treatment","volume":"13","author":"Gonzalez-Suarez","year":"2011","journal-title":"Clin Transl Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0340","doi-asserted-by":"crossref","first-page":"98","DOI":"10.1038\/nature09387","article-title":"Osteoclast differentiation factor RANKL controls development of progestin-driven mammary cancer","volume":"468","author":"Schramek","year":"2010","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2014.12.001_b0345","doi-asserted-by":"crossref","first-page":"2879","DOI":"10.1158\/0008-5472.CAN-12-0044","article-title":"RANK induces epithelial\u2013mesenchymal transition and stemness in human mammary epithelial cells and promotes tumorigenesis and metastasis","volume":"72","author":"Palafox","year":"2012","journal-title":"Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.001_b0350","doi-asserted-by":"crossref","first-page":"29","DOI":"10.1111\/j.1749-6632.2012.06674.x","article-title":"The development of denosumab for the treatment of diseases of bone loss and cancer-induced bone destruction","volume":"1263","author":"Goessl","year":"2012","journal-title":"Ann N Y Acad Sci"},{"key":"10.1016\/j.ctrv.2014.12.001_b0355","doi-asserted-by":"crossref","first-page":"97","DOI":"10.1016\/j.ctrv.2012.07.002","article-title":"Denosumab in patients with cancer and skeletal metastases: a systematic review and meta-analysis","volume":"39","author":"Peddi","year":"2013","journal-title":"Cancer Treat Rev"},{"key":"10.1016\/j.ctrv.2014.12.001_b0360","doi-asserted-by":"crossref","first-page":"3082","DOI":"10.1016\/j.ejca.2012.08.002","article-title":"Superiority of denosumab to zoledronic acid for prevention of skeletal-related events: a combined analysis of 3 pivotal, randomised, phase 3 trials","volume":"48","author":"Lipton","year":"2012","journal-title":"Eur J Cancer"},{"key":"10.1016\/j.ctrv.2014.12.001_b0365","doi-asserted-by":"crossref","first-page":"15","DOI":"10.1517\/14712598.2013.843667","article-title":"Molecular target therapy for bone metastasis: starting a new era with denosumab, a RANKL inhibitor","volume":"14","author":"Rolfo","year":"2014","journal-title":"Expert Opin Biol Ther"},{"key":"10.1016\/j.ctrv.2014.12.001_b0370","doi-asserted-by":"crossref","first-page":"745","DOI":"10.1056\/NEJMoa0809003","article-title":"Denosumab in men receiving androgen-deprivation therapy for prostate cancer","volume":"361","author":"Smith","year":"2009","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.12.001_b0375","doi-asserted-by":"crossref","first-page":"4875","DOI":"10.1200\/JCO.2008.16.3832","article-title":"Randomized trial of denosumab in patients receiving adjuvant aromatase inhibitors for nonmetastatic breast cancer","volume":"26","author":"Ellis","year":"2008","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0380","doi-asserted-by":"crossref","first-page":"1107","DOI":"10.1002\/pds.3477","article-title":"Design and methods of a postmarketing pharmacoepidemiology study assessing long-term safety of Prolia(R) (denosumab) for the treatment of postmenopausal osteoporosis","volume":"22","author":"Xue","year":"2013","journal-title":"Pharmacoepidemiol Drug Saf"},{"key":"10.1016\/j.ctrv.2014.12.001_b0385","doi-asserted-by":"crossref","first-page":"435","DOI":"10.1007\/s00198-010-1326-y","article-title":"Do RANKL inhibitors (denosumab) affect inflammation and immunity?","volume":"22","author":"Ferrari-Lacraz","year":"2011","journal-title":"Osteoporosis Int"},{"key":"10.1016\/j.ctrv.2014.12.001_b0390","doi-asserted-by":"crossref","first-page":"3534","DOI":"10.1182\/blood.V98.13.3534","article-title":"Osteoprotegerin inhibits the development of osteolytic bone disease in multiple myeloma","volume":"98","author":"Croucher","year":"2001","journal-title":"Blood"},{"key":"10.1016\/j.ctrv.2014.12.001_b0395","doi-asserted-by":"crossref","first-page":"887","DOI":"10.1002\/cncr.11138","article-title":"A phase I study of AMGN-0007, a recombinant osteoprotegerin construct, in patients with multiple myeloma or breast carcinoma related bone metastases","volume":"97","author":"Body","year":"2003","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.12.001_b0400","doi-asserted-by":"crossref","first-page":"279","DOI":"10.1042\/CS20050175","article-title":"Role of osteoprotegerin (OPG) in cancer","volume":"110","author":"Holen","year":"2006","journal-title":"Clin Sci"},{"key":"10.1016\/j.ctrv.2014.12.001_b0405","doi-asserted-by":"crossref","first-page":"207","DOI":"10.1007\/s10549-005-2419-8","article-title":"Osteoprotegerin (OPG) expression by breast cancer cells in vitro and breast tumours in vivo \u2013 a role in tumour cell survival?","volume":"92","author":"Holen","year":"2005","journal-title":"Breast Cancer Res Treat"},{"key":"10.1016\/j.ctrv.2014.12.001_b0410","doi-asserted-by":"crossref","first-page":"1794","DOI":"10.1002\/cncr.20550","article-title":"Prognostic significance of serum osteoprotegerin levels in patients with bladder carcinoma","volume":"101","author":"Mizutani","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.12.001_b0415","doi-asserted-by":"crossref","first-page":"138","DOI":"10.1097\/PAT.0b013e32835c9891","article-title":"TRAIL and osteoprotegerin (OPG) expression in bladder urothelial carcinoma: correlation with clinicopathological parameters and prognosis","volume":"45","author":"Levidou","year":"2013","journal-title":"Pathology"},{"key":"10.1016\/j.ctrv.2014.12.001_b0420","doi-asserted-by":"crossref","first-page":"398","DOI":"10.1093\/annonc\/mds277","article-title":"Zoledronic acid (zoledronate) for postmenopausal women with early breast cancer receiving adjuvant letrozole (ZO-FAST study): final 60-month results","volume":"24","author":"Coleman","year":"2013","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0425","doi-asserted-by":"crossref","first-page":"1372","DOI":"10.1038\/nm1518","article-title":"Epidermal RANKL controls regulatory T-cell numbers via activation of dendritic cells","volume":"12","author":"Loser","year":"2006","journal-title":"Nat Med"},{"key":"10.1016\/j.ctrv.2014.12.001_b0430","doi-asserted-by":"crossref","first-page":"841","DOI":"10.1038\/nature02040","article-title":"Osteoblastic cells regulate the haematopoietic stem cell niche","volume":"425","author":"Calvi","year":"2003","journal-title":"Nature"},{"key":"10.1016\/j.ctrv.2014.12.001_b0435","doi-asserted-by":"crossref","first-page":"1269","DOI":"10.4049\/jimmunol.174.3.1269","article-title":"Bone marrow is a preferred site for homeostatic proliferation of memory CD8 T cells","volume":"174","author":"Becker","year":"2005","journal-title":"J Immunol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0440","doi-asserted-by":"crossref","first-page":"R13","DOI":"10.1186\/bcr1384","article-title":"Reduction in bone relapse and improved survival with oral clodronate for adjuvant treatment of operable breast cancer [ISRCTN83688026]","volume":"8","author":"Powles","year":"2006","journal-title":"Breast Cancer Res"},{"key":"10.1016\/j.ctrv.2014.12.001_b0445","doi-asserted-by":"crossref","first-page":"2007","DOI":"10.1093\/annonc\/mdn429","article-title":"Adjuvant oral clodronate improves the overall survival of primary breast cancer patients with micrometastases to the bone marrow: a long-term follow-up","volume":"19","author":"Diel","year":"2008","journal-title":"Ann Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0450","doi-asserted-by":"crossref","first-page":"734","DOI":"10.1016\/S1470-2045(12)70226-7","article-title":"Oral clodronate for adjuvant treatment of operable breast cancer (National Surgical Adjuvant Breast and Bowel Project protocol B-34): a multicentre, placebo-controlled, randomised trial","volume":"13","author":"Paterson","year":"2012","journal-title":"Lancet Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0455","doi-asserted-by":"crossref","first-page":"650","DOI":"10.1080\/02841860410032885","article-title":"Ten-year follow-up of a randomized controlled trial of adjuvant clodronate treatment in node-positive breast cancer patients","volume":"43","author":"Saarto","year":"2004","journal-title":"Acta Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0460","first-page":"377","article-title":"Zoledronic acid versus pamidronate in the treatment of skeletal metastases in patients with breast cancer or osteolytic lesions of multiple myeloma: a phase III, double-blind, comparative trial","volume":"7","author":"Rosen","year":"2001","journal-title":"Cancer J"},{"key":"10.1016\/j.ctrv.2014.12.001_b0465","doi-asserted-by":"crossref","first-page":"3314","DOI":"10.1200\/JCO.2005.05.116","article-title":"Zoledronic acid significantly reduces skeletal complications compared with placebo in Japanese women with bone metastases from breast cancer: a randomized, placebo-controlled trial","volume":"23","author":"Kohno","year":"2005","journal-title":"J Clin Oncol"},{"key":"10.1016\/j.ctrv.2014.12.001_b0470","doi-asserted-by":"crossref","first-page":"2613","DOI":"10.1002\/cncr.20308","article-title":"Long-term efficacy and safety of zoledronic acid in the treatment of skeletal metastases in patients with nonsmall cell lung carcinoma and other solid tumors: a randomized, phase III, double-blind, placebo-controlled trial","volume":"100","author":"Rosen","year":"2004","journal-title":"Cancer"},{"key":"10.1016\/j.ctrv.2014.12.001_b0475","doi-asserted-by":"crossref","first-page":"170","DOI":"10.3816\/CLC.2004.n.030","article-title":"Clinical benefit of zoledronic acid in patients with lung cancer and other solid tumors: analysis based on history of skeletal complications","volume":"6","author":"Hirsh","year":"2004","journal-title":"Clin Lung Cancer"},{"key":"10.1016\/j.ctrv.2014.12.001_b0480","doi-asserted-by":"crossref","first-page":"879","DOI":"10.1093\/jnci\/djh141","article-title":"Long-term efficacy of zoledronic acid for the prevention of skeletal complications in patients with metastatic hormone-refractory prostate cancer","volume":"96","author":"Saad","year":"2004","journal-title":"J Natl Cancer Inst"},{"key":"10.1016\/j.ctrv.2014.12.001_b0485","doi-asserted-by":"crossref","first-page":"488","DOI":"10.1056\/NEJM199602223340802","article-title":"Efficacy of pamidronate in reducing skeletal events in patients with advanced multiple myeloma. Myeloma Aredia Study Group","volume":"334","author":"Berenson","year":"1996","journal-title":"N Engl J Med"},{"key":"10.1016\/j.ctrv.2014.12.001_b0490","doi-asserted-by":"crossref","unstructured":"Pavlakis N, Schmidt R, Stockler M. Bisphosphonates for breast cancer. Cochrane Database Syst Rev. 2005:CD003474.","DOI":"10.1002\/14651858.CD003474.pub2"},{"key":"10.1016\/j.ctrv.2014.12.001_b0495","doi-asserted-by":"crossref","first-page":"453","DOI":"10.2147\/TCRM.S1966","article-title":"Use of ibandronate in the prevention of skeletal events in metastatic breast cancer","volume":"4","author":"Devitt","year":"2008","journal-title":"Ther Clin Risk Manag"}],"container-title":["Cancer Treatment Reviews"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001935?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0305737214001935?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2020,8,27]],"date-time":"2020-08-27T17:40:18Z","timestamp":1598550018000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0305737214001935"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2015,2]]},"references-count":99,"journal-issue":{"issue":"2","published-print":{"date-parts":[[2015,2]]}},"alternative-id":["S0305737214001935"],"URL":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.12.001","relation":{},"ISSN":["0305-7372"],"issn-type":[{"value":"0305-7372","type":"print"}],"subject":[],"published":{"date-parts":[[2015,2]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Crosstalk between bone niche and immune system: Osteoimmunology signaling as a potential target for cancer treatment","name":"articletitle","label":"Article Title"},{"value":"Cancer Treatment Reviews","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ctrv.2014.12.001","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"Copyright \u00a9 2014 Elsevier Ltd. All rights reserved.","name":"copyright","label":"Copyright"}]}}